gypsogenin has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aksel, M; Alankuş, Ö; Bölükbaşı, SŞ; Çiftçi, H; Emirdağ, S; Fujita, M; Karayıldırım, T; Otsuka, M; Özmen, A; Radwan, MO; Sever, B; Sözer, E; Tateishi, H; Ulusoy, NG; Yaylı, N | 1 |
| Ali, TFS; Can, M; Ciftci, HI; Fujita, M; Koga, R; Ocak, Z; Otsuka, M; Ozturk, SE; Radwan, MO; Tateishi, H | 1 |
2 other study(ies) available for gypsogenin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction.
Topics: Apoptosis; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Caryophyllaceae; Cell Survival; Cells, Cultured; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Saponins; Signal Transduction; Triterpenes | 2018 |